TY - JOUR
T1 - Improvement of endothelial function by pitavastatin
T2 - a meta-analysis
AU - Katsiki, Niki
AU - Reiner, Željko
AU - Tedeschi Reiner, Eugenia
AU - Al-Rasadi, Khalid
AU - Pirro, Matteo
AU - Mikhailidis, Dimitri P.
AU - Sahebkar, Amirhossein
N1 - Publisher Copyright:
© 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/2/11
Y1 - 2018/2/11
N2 - Objective. Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk. Pitavastatin has been shown to reduce total and low-density lipoprotein cholesterol, to increase high-density lipoprotein (HDL)-cholesterol and improve HDL function. Furthermore, several trials explored its effects on flow-mediated dilation (FMD), as an index of endothelial function. The authors evaluated the effect of pitavastatin therapy on FMD. Methods. The authors performed a systematic review and meta-analysis of all clinical trials exploring the impact of pitavastatin on FMD. The search included PubMed-Medline, Scopus, ISI Web of Knowledge and Google Scholar databases. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Results. Six eligible studies comprising 7 treatment arms were selected for this meta-analysis. Overall, WMD was significant for the effect of pitavastatin on FMD (2.45%, 95% CI: 1.31, 3.60, p < 0.001) and the effect size was robust in the leave-one-out sensitivity analysis. Conclusion. This meta-analysis of all available clinical trials revealed a significant increase of FMD induced by pitavastatin.
AB - Objective. Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk. Pitavastatin has been shown to reduce total and low-density lipoprotein cholesterol, to increase high-density lipoprotein (HDL)-cholesterol and improve HDL function. Furthermore, several trials explored its effects on flow-mediated dilation (FMD), as an index of endothelial function. The authors evaluated the effect of pitavastatin therapy on FMD. Methods. The authors performed a systematic review and meta-analysis of all clinical trials exploring the impact of pitavastatin on FMD. The search included PubMed-Medline, Scopus, ISI Web of Knowledge and Google Scholar databases. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Results. Six eligible studies comprising 7 treatment arms were selected for this meta-analysis. Overall, WMD was significant for the effect of pitavastatin on FMD (2.45%, 95% CI: 1.31, 3.60, p < 0.001) and the effect size was robust in the leave-one-out sensitivity analysis. Conclusion. This meta-analysis of all available clinical trials revealed a significant increase of FMD induced by pitavastatin.
KW - Pitavastatin
KW - atherosclerosis
KW - endothelial function
KW - flow-mediated dilation
KW - meta-analysis
UR - http://www.scopus.com/inward/record.url?scp=85041111157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041111157&partnerID=8YFLogxK
U2 - 10.1080/14656566.2018.1428560
DO - 10.1080/14656566.2018.1428560
M3 - Article
C2 - 29334477
AN - SCOPUS:85041111157
SN - 1465-6566
VL - 19
SP - 279
EP - 286
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 3
ER -